Theradiag Acquires Prestizia and Its Highly Innovative MicroRNA Technology Platform
Published: Jun 27, 2012
PARIS--(BUSINESS WIRE)--Theradiag, the theranostics and in vitro diagnostics company focused on autoimmune disease, today announced that it is acquiring Prestizia, a biotechnology company that is developing a microRNA1 technology. “The acquisition of Prestizia represents a major advance for Theradiag. Its microRNA platform is going to allow us to strengthen our development in theranostics with a highly innovative, patented technology,” stated Michel Finance, CEO of Theradiag.